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Objective: To investigate the safety and efﬁcacy of ﬁrst-line antimuscarinic monotherapy for men with
predominant storage symptoms in the lower urinary tract based on the International Prostate Symptom
Score (IPSS) voiding-to-storage subscore ratio (IPSS-V/S).
Materials and Methods:We conducted a prospective open-label study of ﬁrst-line tolterodine (4 mg daily)
monotherapy in 132 men (age 41e90 years) with a total IPSS (IPSS-T)  8 and IPSS-V/S  1. The IPSS
storage subscore (IPSS-S), voiding subscore, IPSS-T, quality of life (QoL), maximal ﬂow rate, voided vol-
ume, and post-void residual urine (PVR) were evaluated after treatment for 1 month and 3 months.
Results: The treatment results were satisfactory (global response assessment  1) in 103 men (78.0%).
Mean IPSS-T, IPSS-S, nocturnal frequency, and QoL improved signiﬁcantly. No patient developed acute
urinary retention. However, mean PVR increased signiﬁcantly (from 51.8 to 63.9 mL), especially among
patients older than 70 years. The treatment results did not differ signiﬁcantly between patients with a
total prostate volume (TPV)  30 mL and those with TPV < 30 mL.
Conclusion: First-line antimuscarinic monotherapy is safe and effective for men with IPSS  8 and IPSS-V/
S  1. The treatment results were similar in men with TPV larger or smaller than 30 mL. However, we
recommend that ﬁrst-line antimuscarinic monotherapy in men older than 70 years should be admin-
istered with caution.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Lower urinary tract symptoms (LUTS) include voiding, storage,
and postmicturition symptoms [1]. Although LUTS are not organ-
speciﬁc, most initial treatments for male LUTS focus on the pros-
tate and are traditionally based on a-blockers [2]. Antimuscarinic
therapy is always used as second-line monotherapy or added to a-
blockers when LUTS do not improve or there are persistent storage
symptoms [3e8]. Physicians are usually concerned that the inhib-
itory effect of antimuscarinics might aggravate voiding difﬁculties
or cause urinary retention, especially in men with bladder outlet
obstruction (BOO) [9,10].
Recently updated guidelines indicate that antimuscarinics,
alone or in combination with a-blockers, appear to be an effectiveddhist Tzu Chi General Hos-
an. Tel.: þ03 8561825x2113;
ddhist Compassion Relief Tzu Chiand safe treatment for male storage LUTS, and are suggested as an
alternative treatment for men without elevated post-void residual
urine (PVR) [11e13]. For men with storage LUTS without voiding
LUTS or BOO, antimuscarnicmonotherapy can be used as a ﬁrst-line
treatment. By contrast, combination therapy or sequential use of a-
blockers and antimuscarinics is usually suggested for men with
concomitant signiﬁcant BOO [12e15]. However, in clinical practice,
the presence of BOO is not very clear in some men, and the degree
of BOO is usually difﬁcult to determine without a pressureeﬂow
study. PVR, total prostate volume (TPV), serum prostate-speciﬁc
antigen (PSA), and the maximal ﬂow rate (Qmax) are commonly
used as parameters to guide the treatment choice for male LUTS
[12,13]. However, the parameters that need to be determined
before initiating treatment are still controversial and no cutoff
values have been determined for the safe use of ﬁrst-line anti-
muscarinic monotherapy.
The International Prostate Symptom Score (IPSS) questionnaire
has been used for decades to evaluate the severity of LUTS and
benign prostatic hypertrophy (BPH) [11]. Although the IPSS total
(IPSS-T) score cannot differentiate voiding from storage lowerFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline data.
Total (n ¼ 132) TPV  30 mL
(n ¼ 80)
TPV < 30 mL
(n ¼ 52)
pa
Age (y) 68.6  12.1 71.3  10.2 66.1  1.7 0.018
IPSS-T 14.9  5.6 15.2  5.7 14.3  5.8 0.319
IPSS-V 5.4  3.6 5.5  3.6 5.1  3.7 0.329
IPSS-S 9.5  3.1 9.7  3.3 9.2  2.9 0.379
Nocturia 3.8  1.3 3.8  1.3 3.8  1.2 0.772
QoL 3.9  1.0 3.9  1.0 3.8  0.9 0.436
PSA (ng/mL) 3.9  5.1 5.4  5.3 1.8  3.9 <0.001
TPV (mL) 41.9  26.1 53.0  28.0 23.9  2.9 <0.001
TZI 0.34  0.14 0.38  0.14 0.27  0.11 <0.001
Qmax (mL/s) 13.3  8.2 12.5  7.4 14.3  9.0 0.427
Volume (mL) 214.2  169.1 141.0  16.0 197.0  28.7 0.040
PVR (mL) 50.9  63.3 53.0  66.5 48.3  59.5 0.941
IPSS-S ¼ IPSS storage subscore; IPSS-T ¼ IPSS total score; IPSS-V ¼ IPSS voiding
subscore; PSA ¼ prostate speciﬁc antigen; PVR ¼ post-void residual urine;
Qmax ¼ maximum ﬂow rate; QoL ¼ quality of life index; TPV ¼ total prostate
volume; TZI ¼ transition zone index.
a Comparisons between patients with TPV  30 mL and <30 mL were performed
using the Wilcoxon rank-sum test.
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IPSS subscores and calculation of the IPSS voiding-to-storage sub-
score ratio (IPSS-V/S) are simple and useful methods for differen-
tiating voiding and storage LUTD [16]. To further investigate the
safety and efﬁcacy of ﬁrst-line antimuscarinic monotherapy for
men with predominant storage LUTS based on the IPSS-V/S, espe-
cially for those with a large prostate, we conducted a prospective
open-label study of ﬁrst-line antimuscarinic monotherapy for men
with moderate to severe LUTS (IPSS-T  8) and IPSS-V/S  1,
regardless of their TPV, serum PSA, PVR, or Qmax.
2. Materials and methods
Male patients older than 40 years with IPSS-T>8 were recruited
from January 2010 to December 2010. The IPSS voiding (IPSS-V) and
storage (IPSS-S) subscores were recorded separately according to
the validated Chinese version of the IPSS, and IPSS-V/S was calcu-
lated. Baseline data for TPV, transition zone index (TZI), Qmax, PVR,
voided volume, serum PSA, and quality of life (QoL) index were
obtained. Men with documented genitourinary cancer, acute or
chronic urinary retention, poorly controlled diabetesmellitus, frank
neuropathy, urinary tract infection, or previous urethral surgery
were excluded. Patients with abnormal ﬁndings on digital rectal
examination or elevated serum PSA (4 ng/mL) were referred for a
prostate biopsy to verify the possibility of prostate cancer. Patients
with biopsy-proven prostate cancer were also excluded. The study
was reviewed and approved by the Research Ethics Committee of
Buddhist Tzu Chi General Hospital, and written informed consent
was obtained from each individual.
All menwith IPSS-S greater than or equal to their IPSS-V (IPSS-V/
S 1) received ﬁrst-line tolterodine (4 mg daily) monotherapy,
regardless of their TPV, TZI, Qmax, PVR, or PSA. IPSS-S, IPSS-V, IPSS-
T, QoL, Qmax, voided volume, and PVR. Theywere then evaluated at
1 month (Visit 1) and 3 months (Visit 2) after treatment was
initiated. The treatment results were compared between patients
with TPV 30mL and thosewith TPV< 30mL to investigate if men
with IPSS-V/S  1 and a large prostate can beneﬁt from ﬁrst-line
antimuscarinic monotherapy as much as those with a small
prostate.
Patients rated their symptoms using a global response assess-
ment (GRA), a 7-point scale ranging from markedly worse (3) to
markedly improved (þ3). After treatment for 1month, addition of a
a-blocker or switching to a-blocker monotherapy was done for
patients with GRA <1 based on the investigator’s choice. Parame-
ters were compared between thosewith GRA 1 and GRA< 1 after
antimuscarinic monotherapy for 1 month. We also investigated
possible risk factors for increased PVR (50 mL) and aggravated
IPSS-V (4) after ﬁrst-line tolterodine monotherapy for 1 month.
2.1. Statistical analysis
Continuous variables are presented as mean  standard devia-
tion (SD) and categorical data as number (percentage). Statistical
comparisons between the groups were tested using the c2 test for
categorical variables and the Wilcoxon rank-sum test for contin-
uous variables. Statistical assessments were considered signiﬁcant
for p < 0.05. Statistical analyses were performed using SPSS 15.0
statistical software (SPSS Inc., Chicago, IL, USA).
3. Results
A total of 132 consecutive male patients (age 41e90 years)
received ﬁrst-line tolterodine monotherapy. Mean TPV was 41.6 mL
and mean PSA was 3.9 ng/mL (Table 1). The patients were further
divided into two groups according to their baseline TPV. Patientswith TPV  30 mL were older and had higher serum PSA and lower
voided volumes than those with TPV < 30 mL. However, IPSS-T,
IPSS-V, IPSS-S, QoL, Qmax, and PVR did not signiﬁcantly differ be-
tween the two groups (Table 1).
After ﬁrst-line antimuscarinic monotherapy for 1 month, 103
men (78.0%) demonstrated satisfactory results (GRA  1). For those
with GRA < 1, 22 of 27 men (81.5%) improved to GRA  1 after
combining or switching to a-blocker therapy at the second visit. No
patient developed acute urinary retention. The adverse effects re-
ported included 13 cases of dry mouth (9.8%), 10 of blurred vision
(7.6%), seven of dry eyes (5.3%), six of dysuria (4.5%), three of con-
stipation (2.3%), two of dizziness (1.5%), one of general weakness
(0.8%), and one of palpitations (0.8%).
The parameters at baseline and 1 and 3 months were evaluated
(Fig. 1). Mean IPSS-T, IPSS-S, nocturnal frequency, and QoL
decreased signiﬁcantly. The voided volume increased, but a sig-
niﬁcant increased in PVR (from 51.8mL to 63.9mL) was noted. After
antimuscarinic monotherapy for 1 month, PVR decreased in all ﬁve
patients with baseline PVR  200 mL, and four of these patients
(80%) reported GRA  1. Patients with TPV  30 mL had treatment
results similar to those with TPV < 30 mL (Table 2).
Patients with GRA  1 after tolterodine monotherapy for 1
month had less nocturnal frequency and higher serum PSA at
baseline than those with GRA < 1, whereas the other baseline pa-
rameters were similar (Table 3). When the parameters after treat-
ment for 1 month were compared, patients with GRA  1 also had
lower IPSS-T, IPSS-V, IPSS-S, nocturnal frequency, and QoL, while
Qmax, voided volume, and PVR were similar (Table 3).
After tolterodine monotherapy for 1 month, aggravated IPSS-V
(4) was observed in 22 (16.7%) of 132 patients and increased
PVR (50mL) in 25 (20%) of 125 patients. Most baseline parameters
were similar in patients with and without an increase in PVR or
IPSS-V after treatment. Only age greater than 70 years was signif-
icantly associated with an increase in PVR (50 mL) after tolter-
odine monotherapy (Table 4).
4. Discussion
Our preliminary results demonstrate the safety and efﬁcacy of
ﬁrst-line tolterodine monotherapy in men with IPSS-T  8 and
IPSS-V/S  1. Some 78% of 132 patients reported GRA  1 after
tolterodine monotherapy for 1 month. Mean IPSS-T and IPSS-S
decreased, and quality of life improved signiﬁcantly. No patient
developed urinary retention, but mean PVR increased from 51.8 mL
to 63.9 mL.
Fig. 1. All parameters improved after tolterodine (4 mg daily) monotherapy for 1 month and 3 months. IPSS-T ¼ total IPSS; IPSS-V ¼ IPSS voiding subscore; IPSS-S ¼ IPSS storage
subscore; QoL ¼ quality of life index; Qmax ¼ maximal ﬂow rate; PVR ¼ post-void residual urine. *p < 0.05 compared with baseline.
Table 2
Results for antimuscarinic monotherapy for 1 month.
Total
(n ¼ 132)
TPV  30 mL
(n ¼ 80)
TPV < 30 mL
(n ¼ 52)
p a
DIPSS-T 3.9  0.5 4.1  0.6 3.2  1.0 0.383
DIPSS-V 0.5  0.4 0.5  0.5 0.4  0.8 0.876
DIPSS-S 3.3  0.3 3.6  0.4 2.8  0.4 0.155
DNocturia 0.6  0.1 0.6  0.1 0.6  0.1 0.928
DQoL 1.1  0.1 1.2  0.1 1.0  0.1 0.592
DQmax (mL/s) þ0.19  0.51 þ0.15  0.62 þ0.28  0.94 0.867
DVolume (mL) þ12.5  10.0 þ23.0  12.4 5.4  16.9 0.161
DPVR (mL) þ12.1  5.9 þ13.9  8.3 þ9.0  7.7 0.274
Data expressed as mean  standard error.
IPSS-S ¼ IPSS storage subscore; IPSS-T ¼ IPSS total score; IPSS-V ¼ IPSS voiding
subscore; PVR ¼ post-void residual urine; Qmax ¼ maximum ﬂow rate;
QoL ¼ quality of life index.
a Comparisons between patients with TPV  30 mL and <30 mL were performed
using the Wilcoxon rank-sum test.
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LUTD [16]. Antimuscarinics are the mainstay of pharmacotherapy
for storage LUTD, such as overactive bladder (OAB). A systematic
review revealed that antimuscarinics reduce the severity of ur-
gency, decrease micturition frequency, and improve the quality of
life in patients with OAB [17]. The decreases in mean IPSS-T, IPSS-S,
nocturnal frequency and QoL in our study reﬂect the treatment
results of antimuscarinics in OAB.
Although there is still no consensus on which patients are
suitable for ﬁrst-line antimuscarinic monotherapy, TPV, serum PSA,
PVR, and Qmax are the parameters most commonly used to guide
initial treatment for male LUTS [12,13]. Djavan et al suggested that
antimuscarinic monotherapy is only suitable for men with pre-
dominant storage symptoms, Qmax  10 mL/s, and TPV < 30 mL
[12]. Kaplan et al recommended that antimuscarinic therapy should
be avoided for menwith an enlarged prostate, high serum PSA, and
high PVR or a low ﬂow rate. These suggestions regarding TPV came
in part from a post hoc analysis of the TIMES study (Tolterodine and
Table 3
Results for patients with GRA 1 and GRA< 1 after antimuscarinic monotherapy for
1 month.
GRA  1 (n ¼ 103) GRA < 1 (n ¼ 29) p
Baseline
Age (y) 69.0  12.5 67.2  10.7 0.255
IPSS-T 14.9  5.7 14.7  5.6 0.813
IPSS-V 5.4  3.6 5.2  3.5 0.886
IPSS-S 9.5  3.2 9.5  3.0 0.881
Nocturia 3.6  1.3 4.2  1.1 0.023
IPSS-V/S 0.60  0.32 0.56  0.33 0.561
QoL 3.9  1.0 3.8  1.0 0.578
TPV (mL) 42.1  27.6 41.4  21.2 0.666
TZI 0.35  0.13 0.32  0.15 0.107
PSA (ng/mL) 4.4  5.4 2.5  3.5 0.030
Qmax (mL/s) 13.7  8.6 11.9  6.4 0.447
Volume (mL) 213.8  166.8 215.4  180.1 0.924
PVR (mL) 52.5  62.6 45.1  66.3 0.241
Post-treatment (Visit 1)
IPSS-T 9.8  6.4 15.2  6.7 <0.001
IPSS-V 4.2  4.5 7.0  5.0 0.003
IPSS-S 5.6  3.3 8.2  3.2 <0.001
Nocturia 2.9  1.4 3.9  1.1 0.001
QoL 2.5  1.1 3.6  1.0 <0.001
Qmax (mL/s) 13.5  8.2 12.8  5.7 0.879
Volume (mL) 223.6  155.5 245.0  196.3 0.835
PVR (mL) 62.6  56.1 66.8  80.8 0.692
IPSS-S ¼ IPSS storage subscore; IPSS-T ¼ IPSS total score; IPSS-V ¼ IPSS voiding
subscore; PSA ¼ prostate speciﬁc antigen; PVR ¼ post-void residual urine;
Qmax ¼ maximum ﬂow rate; QoL ¼ quality of life index; TPV ¼ total prostate
volume; TZI ¼ transition zone index.
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and Safety) [18,19]. The analysis revealed that tolterodine mono-
therapy was effective only in patients with TPV < 29 mL, while
combination therapy was effective regardless of prostate size.Table 4
Comparison of baseline parameters between increased IPSS-V of  4 and <4, and
between increased PVR of 50 mL and <50 mL.
Baseline
data
Increased IPSS-V Increased PVR
4 (n ¼ 22) <4 (n ¼ 110) p 50 mL
(n ¼ 25)
<50 mL
(n ¼ 100)
p
Age
70 12 (18.5) 53 (81.5) 0.645 19 (30.2) 44 (69.8) 0.007
<70 10 (14.9) 57 (85.1) 6 (9.7) 56 (90.3)
TPV (mL)
30 12 (15.0) 68 (85.0) 0.474 16 (20.5) 62 (79.5) 1.000
<30 10 (20.4) 39 (79.6) 9 (20.0) 37 (80.0)
TPV (mL)
40 8 (16.7) 40 (83.3) 1.000 11 (23.9) 35 (76.1) 0.489
<40 14 (17.3) 67 (82.7) 14 (18.0) 64 (82.1)
IPSS-T
20 7 (23.3) 23 (76.7) 0.274 4 (13.3) 26 (86.7) 0.433
<20 15 (14.7) 87 (85.3) 21 (22.1) 74 (77.9)
IPSS-V
10 3 (16.7) 19 (83.3) 1.000 1 (5.6) 17 (94.4) 0.120
<10 15 (16.7) 95 (83.3) 24 (22.4) 83 (77.6)
PVR (mL)
50 9 (20.9) 34 (79.1) 0.458 7 (16.3) 36 (83.7) 0.491
<50 13 (14.9) 74 (85.1) 18 (22.0) 64 (78.1)
PVR
100 3 (17.6) 14 (82.4) 1.000 1 (5.9) 16 (94.1) 0.191
<100 19 (16.8) 94 (83.2) 24 (22.2) 84 (77.8)
Qmax (mL/s)
10 11 (14.5) 65 (85.5) 0.349 10 (14.1) 61 (85.9) 0.106
<10 11 (21.2) 41 (78.8) 14 (26.9) 38 (73.1)
PSA (ng/mL)
1.6 10 (13.9) 62 (86.1) 0.346 16 (22.5) 55 (77.5) 0.489
<1.6 12 (21.4) 44 (78.6) 8 (15.7) 43 (84.3)
Data are presented as n (%)., IPSS-T ¼ IPSS total score; IPSS-V ¼ IPSS voiding sub-
score; PSA ¼ prostate-speciﬁc antigen; PVR ¼ post-void residual urine;
Qmax ¼ maximum ﬂow rate; TPV ¼ total prostate volume.The treatment efﬁcacy was similar between men with
TPV  30 mL and those with TPV < 30 mL in our study. The
discrepancy may be due to different inclusion criteria. The TIMES
study was a randomized, double-blind, placebo-controlled trial
evaluating the efﬁcacy and safety of extended-release tolterodine
and/or tamsulosin in men who met research criteria for both
overactive bladder and BPH. The criteria were IPSS  12, frequency
and urgency, with or without urgency urinary incontinence,
PVR< 200mL, and Qmax> 5mL/s, and the study included patients
with both BOO and OAB [5]. We enrolled patients with IPSS-V/S 1
in this study, whereas menwith signiﬁcant BOOwere excluded.We
suggest that IPSS-V/S may be better than TPV in identifying sig-
niﬁcant BOO and determining if ﬁrst-line antimuscarinic mono-
therapy can be initiated. This concept is supported by our previous
retrospective study, which showed the IPSS-V/S is a better predictor
than TPV for urodynamically proved voiding LUTD [16].
We compared baseline parameters between men with GRA  1
and GRA < 1 after treatment for 1 month to identify predictors of
good and poor responders. Men with GRA < 1 had more nocturnal
frequency and lower serum PSA than patients with GRA  1, which
may imply that the prostate or bladder outlet plays less of a role in
LUTS in these patients, and nocturia caused by systemic disease
may partly explain the poor response to antimuscarinic therapy. In
addition, predictors commonly used for poor response to anti-
muscarinic therapy, such as symptom severity, TPV, PVR, and
Qmax, were similar between these groups in our study.
The safety of antimuscarinic monotherapy in men with BOO/
BPH and OAB/detrusor overactivity has been reported in several
studies [5,20e23]. Assessment of baseline PVR prior to initiation of
antimuscarinic therapy is usually suggested [11e15], and anti-
muscarinics should be used with caution in patients with PVR of
250e300 mL [11]. Our study supports this notion, although most of
our patient had baseline PVR of < 200 mL. However, ﬁve of our
patients had baseline PVR  200 mL. After antimuscarinic mono-
therapy for 1 month, PVR decreased in all ﬁve patients, four of
whom (80%) reported GRA  1. More data are still needed to
determine if antimuscarinics can be used safely inmenwith IPSS-V/
S  1 and a large baseline PVR.
We also investigated possible risk factors for increases in PVR
and IPSS-V after antimuscarinics monotherapy. Elderly (70 years)
patients are more likely to have an increase in PVR (50 mL). Other
baseline parameters, such as TPV, IPSS-T, and Qmax, are difﬁcult to
correlate with IPSS-V aggravation or an increase in PVR. Age has
also been reported as a risk factor for BPH progression [24].
Althoughwe reported the safety of add-on antimuscarinics for men
older than 70 years with BPH/BOO [8], we suggest that ﬁrst-line
antimuscarinic monotherapy be used with caution in such men.
One limitation of our study is the lack of a placebo group. We
cannot exclude a possible placebo effect after treatment. In addi-
tion, some patients dropped out. Some patients might have dis-
continued their medication because they felt their symptoms had
improved a lot. The strengths of our study include its prospective
nature and the evaluation of treatment results using both subjec-
tive and objective methods.
5. Conclusions
First-line antimuscarinic monotherapy is safe and effective for
menwith IPSS 8 and IPSS-V/S 1. In this patient group, menwith
a large prostate (30 mL) had treatment results similar to those
with TPV < 30 mL. IPSS-V/S  1 may be worth considering as an
indicator for initiation of antimuscarinic monotherapy. Elderly
(70 years) patients are more likely to have an increased PVR
(50 mL), so ﬁrst-line antimuscarinic monotherapy should be used
with caution in men older than 70 years.
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